Trial Profile

Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixazomib (Primary) ; Dexamethasone; Thalidomide
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

21 Jun 2020 Results evaluating the impact of the oral microbiome on risk factors and/or outcome of patients with multiple myeloma, presented at the 25th Congress of the European Haematology Association
27 Sep 2019 Results published in the British Journal of Cancer
05 Jul 2019 This trial has been completed in Germany(end date: 2019-03-28), according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com